Podcasts about hematology ash

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO Recorded on January 27, 2026 Brad Kahl, MD Professor of Medicine Division of Oncology, Department of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St. Louis, MO In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma, & Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Questions for Our Panel of Expert Speakers

Audio roundup of selected biopharma industry content from Scrip over the business week ended December 12, 2025. This week, a focus on five key results from the American Society of Hematology (ASH) meeting – Jaypirca headed for the front line; Kite's Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia's early in vivo CAR-T data; and Novartis's ianalumab's potential in ITP. Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-RFOOY2665REEZEN5SMJ2GW27EY/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics: Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00) Updated data with belantamab mafodotin for the management of MM (12:39) Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52) ASH 2024 updates with other novel agents and strategies for the management of MM (21:32) CME information and select publications

Featuring an interview with Dr Rafael Fonseca, including the following topics: Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00) Sequencing bispecific antibodies and CAR T-cell therapy (10:40) Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03) Optimizing maintenance therapy for patients with MM (31:11) Novel management strategies for smoldering myeloma (36:29) Role of anti-CD38 antibodies in the up-front management of MM (41:41) Available data with cereblon E3 ligase modulatory drugs for MM (47:45) CME information and select publications

Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.

Featuring an interview with Dr Lindsey Roeker, including the following topics: Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00) Safety of BTK inhibitors in older and frail patients with CLL (3:41) Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20) Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32) Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31) Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16) Sequencing, tolerability and future development involving pirtobrutinib (25:57) Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28) Clinical considerations in the management of Richter's transformation (38:14) Survival outcomes and quality of life for patients with CLL (41:02) Ongoing and future efforts to improve CLL treatment outcomes (45:01) CME information and select publications  

Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics: Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00) Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03) Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35) Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28) Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52) Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12) Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38) Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15) Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13) Available data with epcoritamab monotherapy for R/R CLL  (26:58) The emerging pharmacologic class of BTK degraders  (29:04) CME information and select publications

Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications

Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications

Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics: Overview of the current JAK inhibitor landscape (0:00) Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02) Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17) Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13) Available clinical data with novel BET inhibitors (15:00) Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50) Emerging efficacy and safety findings reported with imetelstat for MF (18:57) Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15) Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05) Other novel agents and strategies under investigation for MF (26:06) CME information and select publications

Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.

Join Dr. Madanat (UT Southwestern, Texas), Dr. Stahl (Harvard Medical School, Massachusetts), and Dr. Papadantonakis (Emory University, Georgia) as they break down key Myelodysplastic Syndromes (MDS) abstracts from the 2024 American Society of Hematology (ASH) meeting.Tune in to gain valuable insights and stay informed about the evolving landscape of MDS management.

This episode of the VJHemOnc podcast covers updates in non-malignant hematological diseases from the 66th American Society of Hematology (ASH)... The post Post-ASH non-malignant highlights: updates in sickle cell disease, thalassemia, and hemophilia appeared first on VJHemOnc.

This podcast is the second episode in our series spotlighting key highlights from the 66th American Society of Hematology (ASH)... The post Post-ASH MDS highlights: managing anemia in LR-MDS and novel approaches to treating HR-MDS appeared first on VJHemOnc.

The involvement of oncology fellows in state policy and advocacy efforts is essential for enhancing cancer care and advancing research. The Association of Cancer Care Centers (ACCC) provides up-to-date information and opportunities for oncology advocacy, helping oncologists early in their career to be aware of how to contribute to local, state, and national initiatives. In this episode, CANCER BUZZ speaks with Katherine Baker, MD, medical director of value-based care and medical oncologist at Tennessee Oncology, to discuss her experience in engaging in advocacy efforts with the American Society of Hematology (ASH), the Community Oncology Alliance (COA), and her current role as a board member on the Tennessee Oncology Practice Society (TOPS) advocacy committee. We also hear from Haley M Simpson, MD, PhD, physician-scientist, Division of Hematology at the University of Colorado, about the direct impact of advocacy on patient care.   “To me, forming coalitions through these [national] organizations is essential for driving meaningful, long lasting policy change, as collective voices are often much stronger and more impactful than individual efforts on your own.” -Katherine Baker, MD   “By getting involved in advocacy and policy earlier in your career, it has all the more ability to amplify the impact for patients.” -Haley Simpson, MD, PhD   Katherine Baker, MD, MMHC Medical Director of Value-Based Care and Medical Oncologist Tennessee Oncology Nashville, TN   Haley M. Simpson, MD, PhD Physician-Scientist, Division of Hematology University of Colorado Aurora, CO   This podcast is part of the Oncology State Societies (OSS) Policy and Advocacy program, made possible through the support of Johnson & Johnson.   Please visit your state society's website for potential fellowship opportunities, which you can find here. For any questions or to learn about upcoming events and opportunities, feel free to email Amanda Impellizzeri directly at aimpellizzeri@accc-cancer.org.   Resources ACCC and OSS Advocacy Engagement Initiative  ACCC Legislative Action Center  NCCN Policy Fellows Program  ASCO Advocacy Resources  ASCO Fellows Resources

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts

This week, GSK and Gilead and Arcellx presented key data at the American Society of Hematology (ASH) annual meeting as they vie for a competitive advantage in multiple myeloma. Meanwhile, Vertex unveiled positive long-term data for its CRISPR Therapeutics–partnered gene therapy Casgevy in sickle cell disease—results BMO Capital Markets analysts said should help Casgevy keep its edge over bluebird bio's Lyfgenia. On that note, Casgevy and Lyfgenia have a new outcomes-based payment model after the Centers for Medicare and Medicaid Service (CMS) said both companies have agreed to participate in a voluntary program to improve access to the gene therapies. Speaking of access, Eli Lilly and Novo Nordisk both announced significant manufacturing investments aimed at shoring up production of their diabetes and weight loss blockbusters tirzepatide and semaglutide. And in related news, the European Commission gave its blessing to Novo Holdings' controversial acquisition of contract manufacturing firm Catalent. Elsewhere, AbbVie got a much-needed win for Cerevel-acquired Parkinson's disease therapy tavapadon—a month after the deal's cornerstone asset emraclidine failed in schizophrenia—while uniQure announced it has aligned with the FDA on “key elements” of the accelerated approval pathway for its investigational gene therapy for Huntington's, AMT-130.

On the latest BioCentury This Week podcast, Washington Editor Steve Usdin and colleagues discuss how President-elect Donald Trump's pick to lead NIH, Jay Bhattacharya, would lead NIH and how that could affect the biopharma industry.The BioCentury team then discusses its analysis of abstracts released ahead of the American Society of Hematology (ASH) and Society for Immunotherapy of Cancer (SITC) annual conferences, highlighting methods for applying dual or bispecific CAR T cell designs to solid tumors. And they also analyze FDA approvals of products by biotech companies, noting that current trends show biotechs shedding their reliance on pharma to get drugs across the finish line for approval.View full story: https://www.biocentury.com/article/65436300:00 - Introduction01:08 - Trump's NIH Pick12:13 - Multi-targeted CAR Ts19:26 - Biotech FDA ApprovalsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

In this Trendsetter Tuesday podcast, Meetings Today digital content coordinator Logan Pratt sat down with Bill Reed, Chief Event Strategy Offer for the American Society of Hematology (ASH) and one of this year's Meetings Trendsetters. Reed talks about his journey in the meetings industry to this point, why he is always asking questions and innovating and why he is never complacent with the status quo.

MDS experts Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss new trials presented in the last meeting of the American Society of Hematology (ASH) 2023. They focus on luspatercept, imetelstat and roxodustat.  

Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept, imetelstat, roxodustat and Ker-050.  

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024 Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

It wasn't even two weeks into the new year when the Food and Drug Administration made their first FDA approval. In this case, it was a Keytruda regimen for certain patients with gynecologic cancers. We at CURE® spoke with an the primary investigator on the study leading to the approval about what patients need to know about the latest new indication.  Also last week, we highlighted the Lymphedema Treatment Act and spoke to an expert about the new law.  Another story in the regulatory space: the FDA granted a Fast Track designation to speed up the review of a novel drug used to treat patients with relapsed or refractory CLL or SLL.  Finally, research from the American Cancer Society showed that Medicaid expansion states tended to have improved post-surgical outcomes in patients with non-small cell lung cancer.   Keytruda Plus CRT Offers ‘Better Chance of Cure' in Advanced Cervical Cancer The Food and Drug Administration has granted approval for Keytruda (pembrolizumab) in combination with chemoradiotherapy for the treatment of stages 3 to 4A cervical cancer, marking the first approval of an anti-PD-1 therapy with chemotherapy for this patient population and the third FDA approval for treating cervical cancer with Keytruda.  This week, I spoke with Dr. Linda R. Duska, a gynecologic oncologist and principal investigator on the study leading to the approval, who discussed the KEYNOTE-A18 trial, which enrolled 1,060 patients and demonstrated a 30% decrease in progression for those receiving the combination of Keytruda and chemotherapy. The overall survival data is not yet mature, but the treatment showed a 41% reduction in the risk of disease progression or death. While Dr. Duska emphasized that cervical cancer is preventable thanks to a safe and effective vaccine, she said that for patients with the disease, this new regimen is particularly exciting.  January is also Cervical Cancer Awareness month, so definitely stay tuned to curetoday.com for more of our coverage on the disease.  Medicare Must Now Cover Lymphedema Treatment Garments The Lymphedema Treatment Act, signed into federal law on Dec. 23, 2022, is now in effect as of Jan. 1, 2024, allowing Medicare coverage for doctor-prescribed compression supplies for patients experiencing. The bill encompasses standard and custom-fitted gradient compression garments and other approved items prescribed by healthcare professionals to treat lymphedema. Now basically what that means is that patients insured by Medicare Part B can now have their lymphedema garments covered by insurance.  This coverage is expected to ease financial burdens on patients, especially as these garments can be expensive.  I spoke with Joanna Fawzy Doran, CEO of Triage Cancer, who emphasized the importance of patient and provider awareness about coverage rights, appealing denials and navigating the process. Although the law does not mandate private insurers to cover compression sleeves for lymphedema patients, Doran noted that Medicare's coverage sets a precedent for broader access in the future. FDA Grants NX-5948 Fast Track Designation for R/R CLL, SLL The FDA has granted Fast Track designation to NX-5948, a novel drug, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously undergone two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.  Fast Track designation aims to expedite the development and review of drugs addressing serious conditions with unmet medical needs.  NX-5948 is currently in a Phase 1a/1b clinical trial, with initial findings presented at the 2023 American Society of Hematology (ASH) annual meeting indicating safety, tolerance, and clinical activity. The drug showed no dose-limiting toxicities or treatment-related side effects leading to discontinuation, and the most common side effects were purpura/contusion, nausea, and thrombocytopenia.  Medicaid Expansion May Decrease Early Mortality in Some With NSCLC States with Medicaid expansion tended to have a significant decrease in early, postoperative mortality from non-small cell lung cancer, according to recent research.  The research focused on nearly 15,000 patients undergoing surgery for NSCLC, with 62.1% residing in states supporting Medicaid expansion. The study found notable reductions in 30-day and 90-day postoperative mortality in patients with stages 1, 2, or 3 NSCLC in expansion states. Patients in non-expansion states were found to be younger, non-Hispanic Black, uninsured, and with comorbidities.  The study also evaluated changes in early mortality before and after the Affordable Care Act (ACA) implementation, showing a decrease in the 30-day mortality rate in expansion states from 0.97% to 0.26% after the ACA. Now, advocates, including the American Cancer Society, continue to emphasize the importance of expanding Medicaid eligibility to improve health outcomes.  For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate: - TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis - MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis - SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML - AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results   #ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman: - ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - SEQUOIA: Ph 3, Broad Superiority of Zanubrutinib Over BR Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Treatment-Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p) - SWOG S1826: Nivolumab-AVD Is Better Tolerated and Improves PFS Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma - POLARIX Update: Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: - PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT) - IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM - Bortezomib Dosing - Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM - KarMMA-3 Update - Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis

Signals from the Fed that rate cuts are on the way rallied biotech indexes last week, but is the uptick more than a blip? On the latest BioCentury This Week podcast, BioCentury's editors discuss how interest rate cuts could spur a risk-on rotation back into the sector by generalist investors, the possibility of biotech outperformance in 2024, and what it will take for the IPO window to open. They also assess progress demonstrated by companies' with next-generation gene editors at this year's American Society of Hematology (ASH) meeting, as well as BioCentury's analysis of new targets at the conference. The editors also offer their picks for the highlights (and lowlights) of 2023 and predictions for what's in store in the New Year.Music for the 24th Bio€quity Europe teaser produced by:Thomas de Paula Eby, Andreas Unge, Epidemic Sound via Getty Images

Dr. John Leonard shares his list of the 10 most interesting lymphoma-related abstracts to be presented at the 2023 meeting of the American Society of Hematology (ASH). The ASH annual meeting brings together blood cancer experts from around the world to present the most exciting research in the field. This annual special episode features an in-depth look at this year's cutting-edge research and also features 5 “bonus” podcast-only abstract selections. Host: John Leonard, MD, a leading hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.